Human Gene TherapyVol. 27, No. 7 Correction NoticesFree AccessCorrection to: Hum Gene Ther 2016;27(6):436–450Published Online:18 Jul 2016https://doi.org/10.1089/hum.2015.148.correxAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail In the June 2016 issue of Human Gene Therapy (vol. 27, no. 7, pp. 436–450), in the article “Establishment of Functional Genomics Pipeline in Epiblast-Like Tissue by Combining Transcriptomic Analysis and Gene Knockdown/Knockin/Knockout, Using RNA Interference and CRISPR/Cas9,” by Dr. Nozomu Takata et al., the authors wish to introduce a few changes to clarify mouse rather than human materials were the subject of this study. The authors would like to change the listed title to read:“Establishment of Functional Genomics Pipeline in Mouse Epiblast-Like Tissue by Combining Transcriptomic Analysis and Gene Knockdown/Knockin/Knockout, Using RNA Interference and CRISPR/Cas9”They would like to introduce the word “mouse” in the abstract where it reads, “In the present study, using the self-organizing properties of embryonic stem cell (ESC), we generated and characterized epiblast-like tissue in three-dimensional culture.” to read, “In the present study, using the self-organizing properties of mouse embryonic stem cell (ESC), we generated and characterized epiblast-like tissue in three-dimensional culture.” And in the text again insert the word “mouse” so the passage that currently reads, “In this study, we used a 3-D culture method to characterize epiblast-like tissue, to analyze its whole transcriptome, and to manipulate its genes by genome editing and inducible RNA interference (RNAi).” now reads as, “In this study, we used a 3-D culture method to characterize mouse epiblast-like tissue, to analyze its whole transcriptome, and to manipulate its genes by genome editing and inducible RNA interference (RNAi).”The authors have also removed the word “targeting” from the sentence, “We first designed Fgf5 gRNA sequences (see Materials and Methods) and constructed Fgf5 CRISPR/Cas9 targeting vectors (hereafter referred to as gRNA1, gRNA2, and gRNA3) (Fig. 3A).” so it now reads, “We first designed Fgf5 gRNA sequences (see Materials and Methods) and constructed Fgf5 CRISPR/Cas9 vectors (hereafter referred to as gRNA1, gRNA2, and gRNA3) (Fig. 3A).”The online version of the article has been corrected to reflect these changes.The authors wish to apologize for the inaccuracies.FiguresReferencesRelatedDetails Volume 27Issue 7Jul 2016 InformationCopyright 2016, Mary Ann Liebert, Inc.To cite this article:Correction to: Hum Gene Ther 2016;27(6):436–450.Human Gene Therapy.Jul 2016.560-560.http://doi.org/10.1089/hum.2015.148.correxPublished in Volume: 27 Issue 7: July 18, 2016PDF download